LexisNexis is teaming up with Harvey. Here's why that matters for the legal tech market.
The partnership lets Harvey users who also subscribe to LexisNexis access its deep trove of legal content and citations directly within Harvey's app — a hookup that strengthens Harvey's claim as the go-to provider of legal software. The integration launches later this year.
Harvey's software assists lawyers with legal drafting and review. However, its product had a gaping hole. It provided users with access to public case law databases but not LexisNexis or Westlaw, which control a majority share of the market for legal information services.
With LexisNexis data baked into its interface, Harvey has a stronger case to make to law firms and a better shot at defending its early lead in the legal tech arms race.
Founded in 2022, Harvey shot to stardom in the legal tech space with backing from OpenAI and Sequoia. Today, over a quarter of the country's 100 largest law firms count themselves as users.
Ropes & Gray — the seventh highest-grossing firm — rolled out Harvey firmwide in June after a year of use with a smaller test group, according to Ed Black, the firm's technology strategy leader. This came on the heels of Paul Weiss announcing it co-developed a custom workflow builder with Harvey.
These moves reflect a broader trend in Big Law as more firms shift from cautious pilot programs to full-scale deployments. The change could ratchet up pressure on startups like Harvey, Legora, Hebbia, and Eudia, all vying for the same budgets and attention from top firms and legal departments.
Sean Fitzpatrick, CEO of LexisNexis North America, UK, and Ireland, said the idea for the partnership came from customers, many of whom were toggling between the two platforms as part of their regular workflow. He noted that most of Harvey's large law firm clients are also LexisNexis customers.
While LexisNexis offers its own tools for drafting and legal research, Fitzpatrick said customers still saw value in having access to both platforms.
Harvey is "compensating" LexisNexis for the data, but declined to share any further details
In a move that hinted at deeper ties, Relx, the parent company of LexisNexis, invested in Harvey in February through its corporate venture arm, Rev Ventures, which invests in early data and analytics companies across industries. The $300 million round was one of the largest in legal tech history, catapulting Harvey's valuation to $3 billion.
But LexisNexis' intentions weren't always so clear. Just a month later, at the Legalweek conference in New York City, Fitzpatrick offered little love for legal tech startups. During a panel, he appeared to downplay the threat of companies like Harvey and Legora while touting his own company's goods.
He said that while he couldn't speak for the competition, LexisNexis had one key advantage: data. The company was focused on making sure its chatbot answers were grounded in "authoritative content" — the kind that, in his words, gave the system credibility in a field where "veracity matters … a lot."
Harvey CEO Winston Weinberg, in a statement, described the partnership as a step toward more efficient legal workflows. Lawyers will be able to ask Harvey questions in plain English, follow up with clarifying prompts, and get responses linked to primary sources — assuming they're also Lexis subscribers.
How seamlessly this works in practice remains to be seen.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
10 hours ago
- Yahoo
Arvinas, Pfizer's Vepdegestrant NDA Accepted by FDA for Breast Cancer Treatment
Arvinas Inc. (NASDAQ:ARVN) is one of the best small cap stocks with biggest upside potential. On August 8, Arvinas, in collaboration with Pfizer Inc. (NYSE:PFE), announced that the US FDA accepted its New Drug Application/NDA for vepdegestrant. The drug is intended to treat patients with estrogen receptor-positive/ER+, human epidermal growth factor receptor 2-negative/HER2-, ESR1-mutated advanced or metastatic breast cancer who have already received endocrine-based therapy. The FDA has set a Prescription Drug User Fee Act/PDUFA action date of June 5, 2026. The NDA is based on data from the Phase 3 VERITAC-2 clinical trial, which showed a statistically significant and clinically meaningful improvement in median progression-free survival for vepdegestrant compared to fulvestrant. The trial enrolled 624 patients at 213 sites across 25 countries, with 270 of these patients having the ESR1 mutation. A biopharma executive in a meeting room discussing the clinical-stage of a new therapy. The results from this trial were recently presented at the American Society of Clinical Oncology/ASCO 2025 Annual Meeting and published in The New England Journal of Medicine. Vepdegestrant is an investigational oral drug that functions as a PROteolysis TArgeting Chimera/PROTAC estrogen receptor degrader. This marks the first time a PROTAC has demonstrated a clinical benefit in breast cancer patients. Arvinas Inc. (NASDAQ:ARVN) is a clinical-stage biotechnology company that engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Pfizer Inc. (NYSE:PFE) discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the US and internationally. While we acknowledge the potential of ARVN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Chicago Tribune
2 days ago
- Chicago Tribune
Southland road work, bike path projects to receive Cook County grants
Several south and southwest suburbs are getting Cook County grant money for transportation projects such as repaving streets and building bike paths. Nearly $8.3 million in grants for 32 projects were announced last week by Cook County. The county awarded $300,000 to Calumet City to install stormwater bumpouts on Wentworth Avenue at 156th Street and 156th Place. Calumet Park will get $350,000 for design and construction of alley improvements in the village. The county awarded $300,000 to Harvey for engineering work on a project to make improvements along 157th Street between West Avenue and Dixie Highway in an industrial area of the city. Oak Forest will get $416,000 to build a bike and walking trail along Central Avenue north of 159th Street. The trail will connect with the existing Tinley Creek trail and also make sections of Oak Forest more accessible by foot or bike, including City Hall, Central Park, the library and Oak Forest High School, according to the county. The county awarded $306,000 to the Oak Lawn Park District for a bike and walking path at the Wolfe Wildlife Park, 109th Street and Laramie Avenue. The work will involve replacing and widening an existing asphalt path, installing lighting and building a new path along the east side of Richards High School, according to the county. Orland Park plans to make safety improvements at 159th Street and 94th Avenue, bordering Orland Hills, and will get $150,000 toward design of the work. Palos Hills will get $270,000 to make pedestrian safety improvements along 111th Street. Phoenix will get $430,000 toward design and construction of road improvements along 7th Avenue from 153rd Street to 155th Street. Resurfacing of the street comes after installation of a new water main on 7th Avenue. The county awarded $240,000 to Richton Park to design a rebuild of Richton Road, including making it a two-way street with a center turn lane. Tinley Park will receive $250,000 to make road improvements along 179th Street between 80th Avenue and 94th Avenue. Resurfacing the road is planned along with new sidewalks, according to the county. The funds come from the Invest in Cook program, which earmarks grants for transit projects. County officials said 63% of funds this year will go to projects in low- and moderate-income areas. They said in some projects funded, county money is leveraged with local, state or federal money to widen the scope of work. This the ninth year Invest in Cook money has been distributed, with a total over that time of more than $72 million.
Business Wire
7 days ago
- Business Wire
Quince Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, today provided an update on the company's development pipeline and reported financial results for the second quarter ended June 30, 2025. Dirk Thye, M.D., Quince's Chief Executive Officer and Chief Medical Officer, said, 'We achieved many critical milestones over the last quarter that significantly advance our research programs and strengthen our business model. Specifically, we completed enrollment in our pivotal Phase 3 NEAT clinical trial, secured additional financing to extend our operating runway sufficiently beyond topline results, and solidified our commercial development planning through our strategic partnership with Option Care Health. Quince remains confident in our ability to deliver topline results in the first quarter of 2026 and subsequent NDA submission in the second half of 2026, assuming positive study results.' Pivotal Phase 3 NEAT Clinical Trial Quince completed enrollment in its pivotal Phase 3 NEAT (N eurological E ffects of eDSP on Subjects with A - T; NCT06193200 / IEDAT-04-2022) clinical trial with a total of 105 participants, including 83 participants in the six to nine year-old primary analysis population and 22 participants aged 10 years and older. Quince expects to report topline results from its Phase 3 NEAT clinical trial in the first quarter of 2026. Concluding the NEAT study with 83 enrolled participants in the six to nine year-old primary analysis population reflects powering of approximately 90% to determine statistical significance of the primary endpoint. All 50 NEAT participants to date have elected to transition to the open label extension (OLE) study (NCT06664853 / IEDAT-04-2022). Participants who complete the full treatment period, complete study assessments, and provide informed consent are eligible to transition to the OLE study. The Phase 3 NEAT clinical trial is being conducted under a Special Protocol Assessment (SPA) agreement with the U.S. Food and Drug Administration (FDA). Assuming positive study results, the company plans to submit a New Drug Application (NDA) to the FDA in the second half of 2026. Quince was granted FDA Fast Track designation for the company's eDSP System for the treatment of patients with A-T based on the potential to address a high unmet medical need. NEAT is an international, multicenter, randomized, double-blind, placebo-controlled clinical trial to evaluate the neurological effects of Quince's lead asset, eDSP (dexamethasone sodium phosphate [DSP] encapsulated in autologous red blood cells; previously referred to as EryDex) in patients with A-T. Participants are randomized (1:1) between eDSP or placebo and treatment consists of six infusions scheduled once every 21 to 30 days. The primary efficacy endpoint will be measured by the change from baseline to last efficacy visit using the Rescored modified International Cooperative Ataxia Rating Scale (RmICARS) compared to placebo. Pipeline and Corporate Updates Announced a strategic relationship with Option Care Health, Inc. (Nasdaq: OPCH), the nation's largest independent provider of home and ambulatory infusion services, to support the commercial development and efficient launch of Quince's lead asset, eDSP, in the U.S. The strategic relationship will leverage Option Care's robust network of specialty pharmacy and ambulatory infusion suites to provide for the administration of eDSP in an effective and efficient way while delivering this innovative treatment to patients with greater geographic flexibility. Closed a private placement of common stock and accompanying warrants in June 2025 led by healthcare-focused institutional investor Nantahala Capital with participation from existing Quince stockholders including ADAR1 Capital Management, Legend Capital Partners, and Lagfin S.C.A., new stockholder Second Line Capital, along with members of Quince's senior management. Priced at a more than a 10% premium to the market price of Quince's common stock, the financing resulted in approximately $11.5 million in upfront proceeds and potential additional proceeds of up to $10.4 million, if the accompanying warrants are exercised in full, before deducting placement agent fees and other private placement expenses. Finalized Phase 2 clinical trial study designs to evaluate eDSP for the potential treatment of patients with Duchenne muscular dystrophy (DMD), the company's second targeted indication for its lead asset, eDSP. Quince plans to prioritize capital efficient study approaches, including potential investigator-initiated trials (IITs), to advance the evaluation of DMD as a second targeted eDSP indication. Initiated Study #3 in the company's European Union pediatric investigational plan (PIP) – named the P ediatric E ncapsulated D examethasone Sodium Phosphate (PeD) study – to evaluate the safety and pharmacokinetics of eDSP in younger patients with A-T who weigh between nine and 15 kilograms. Participated at the 2025 A-T Clinical Research Conference organized by the A-T Society, a leading A-T patient advocacy group based in the United Kingdom, where key opinion leaders (KOLs) presented post hoc data analyses from the company's prior Phase 3 ATTeST clinical trial, in addition to Quince management providing an overview of the Phase 3 NEAT clinical trial. Appointed Dr. Hassan Abolhassani, Assistant Professor of Clinical Immunology and Research Specialists in the Department of Medical Biochemistry and Biophysics at the Karolinska Institutet in Stockholm, Sweden, to the company's Scientific Advisory Board (SAB). Dr. Abolhassani becomes the ninth member to join Quince's SAB, which is comprised of leading experts in A-T, biochemistry, neurology, immunology, genetic, hematology, pharmacology, and clinical practice. Second Quarter 2025 Financial Results Reported cash, cash equivalents, and short-term investments of $34.7 million for the second quarter ended June 30, 2025. Quince expects its existing cash runway to be sufficient to fund the company's capital efficient development plan through Phase 3 NEAT topline results into the second quarter of 2026. If warrants related to the company's recent financing are exercised in full for cash, Quince's cash runway would extend into the second half of 2026. Reported research and development (R&D) expenses of $6.6 million for the second quarter ended June 30, 2025. R&D expenses primarily included costs related to ongoing Phase 3 NEAT clinical trial activities and related manufacturing costs. Reported general and administrative (G&A) expenses of $3.3 million for the second quarter ended June 30, 2025. G&A expenses primarily included personnel-related and stock-based compensation expenses, commercial planning and new product planning expenses, and other professional administrative costs. Reported a net loss of $16.1 million, or a net loss of $0.34 per basic and diluted share, for the second quarter ended June 30, 2025. Weighted average shares outstanding for the year were 46.7 million. Reported net cash used in operating activities of $21.0 million for the six months ended June 30, 2025. Cash used in operating activities was primarily due to net loss of $31.1 million for the period, adjusted for $9.9 million of non-cash items, including $4.5 million change in the fair value of warrants, $2.7 million in stock-based compensation, $2.5 million change in the fair value of contingent consideration liabilities, $0.8 million change in the fair value of the European Investment Bank loan, and a net decrease in operating assets of $0.5 million, offset by a net increase in accounts payable, and accrued expenses, and other current liabilities of $0.3 million. About Quince Therapeutics Quince Therapeutics, Inc. (Nasdaq: QNCX) is a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases. For more information on the company and its latest news, visit and follow Quince on social media platforms LinkedIn, Facebook, X, and YouTube. Forward-looking Statements Statements in this news release contain 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the 'safe harbor' created by those sections. All statements, other than statements of historical facts, may be forward-looking statements. Forward-looking statements contained in this news release may be identified by the use of words such as 'believe,' 'may,' 'should,' 'expect,' 'anticipate,' 'plan,' 'believe,' 'estimated,' 'potential,' 'intend,' 'will,' 'can,' 'seek,' or other similar words. Examples of forward-looking statements include, among others, statements relating to the timing, success, and reporting of results of the clinical trials and related data, including expected timing of Phase 3 NEAT topline results and submission of a related NDA; expected cash position and operating runway, including cash potentially receivable upon the exercise of warrants; current and future clinical development of eDSP, including for the potential treatment of Ataxia-Telangiectasia (A-T), Duchenne muscular dystrophy (DMD), and other potential indications; the strategic development path for eDSP, including the anticipated benefits of the strategic partnership with Option Care Health; planned regulatory agency submissions and clinical trials and timeline, prospects, and milestone expectations; and the potential benefits of eDSP and the company's market opportunity. Forward-looking statements are based on Quince's current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict and could cause actual results to differ materially from what the company expects. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Factors that could cause actual results to differ include, but are not limited to, the risks and uncertainties described in the section titled 'Risk Factors' in the company's Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on March 24, 2025, Quarterly Report on Form 10-Q filed with the SEC on May 13, 2025, and other reports as filed with the SEC. Forward-looking statements contained in this news release are made as of this date, and Quince undertakes no duty to update such information except as required under applicable law.
